Literature DB >> 8240346

Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase.

Y Moriyama1, V Patel, I Ueda, M Futai.   

Abstract

Vacuolar-type H(+)-ATPase from adrenal chromaffin granules was found to be sensitive to omeprazole, a known gastric H+/K(+)-ATPase inhibitor, the concentration required for 50% inhibition being 80 microM freshly-prepared and 12 microM acid-treated reagent. ATP and ADP protected the enzyme from inhibition by omeprazole. The activity of the inhibited enzyme was restored by the addition of reduced glutathione. Omeprazole protected the enzyme from inhibition by N-ethylmaleimide and its binding to the subunit A. As subunit A has a nucleotide binding site(s) and as a cysteine residue is involved in the inhibition by N-ethylmaleimide, these results suggested that the two sulfhydryl reagents bind to the same cysteine residue near the nucleotide binding domain in the subunit A, resulting in inactivation of vacuolar-type H(+)-ATPase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240346     DOI: 10.1006/bbrc.1993.2306

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Proton pump inhibitors have pH-dependent effects on the thermostability of the carboxyl-terminal domain of voltage-gated proton channel Hv1.

Authors:  Qing Zhao; Weiyan Zuo; Shangrong Zhang; Yongqiang Zhang; Chuanyong Li; Shu Jie Li
Journal:  Eur Biophys J       Date:  2017-09-09       Impact factor: 1.733

Review 2.  Disrupting proton dynamics and energy metabolism for cancer therapy.

Authors:  Scott K Parks; Johanna Chiche; Jacques Pouysségur
Journal:  Nat Rev Cancer       Date:  2013-09       Impact factor: 60.716

3.  Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD.

Authors:  Manuela Salerno; Sofia Avnet; Gloria Bonuccelli; Shigekuni Hosogi; Donatella Granchi; Nicola Baldini
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

4.  Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.

Authors:  Xiaoyu Zeng; Lin Liu; Mengzhu Zheng; Huimin Sun; Juanjuan Xiao; Tao Lu; Guangqian Huang; Pianpian Chen; Jianmin Zhang; Feng Zhu; Hua Li; Qiuhong Duan
Journal:  Oncotarget       Date:  2016-04-19

5.  Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells.

Authors:  Eduardo Chueca; Nadezda Apostolova; Juan V Esplugues; María A García-González; Ángel Lanas; Elena Piazuelo
Journal:  Front Pharmacol       Date:  2016-11-25       Impact factor: 5.810

6.  Proton pump inhibitors for the treatment of cancer in companion animals.

Authors:  Megan Walsh; Stefano Fais; Enrico Pierluigi Spugnini; Salvador Harguindey; Tareq Abu Izneid; Licia Scacco; Paula Williams; Cinzia Allegrucci; Cyril Rauch; Ziad Omran
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04

7.  Aberrant autolysosomal regulation is linked to the induction of embryonic senescence: differential roles of Beclin 1 and p53 in vertebrate Spns1 deficiency.

Authors:  Tomoyuki Sasaki; Shanshan Lian; Jie Qi; Peter E Bayliss; Christopher E Carr; Jennifer L Johnson; Sujay Guha; Patrick Kobler; Sergio D Catz; Matthew Gill; Kailiang Jia; Daniel J Klionsky; Shuji Kishi
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

8.  Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma.

Authors:  Enrica Balza; Patrizia Castellani; Paola Sanchez Moreno; Patrizia Piccioli; Iria Medraño-Fernandez; Claudia Semino; Anna Rubartelli
Journal:  Oncotarget       Date:  2017-06-27

9.  Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma.

Authors:  Gemma Di Pompo; Silvia Lemma; Lorenzo Canti; Nadia Rucci; Marco Ponzetti; Costantino Errani; Davide Maria Donati; Shonagh Russell; Robert Gillies; Tokuhiro Chano; Nicola Baldini; Sofia Avnet
Journal:  Oncotarget       Date:  2017-04-13

10.  Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.

Authors:  Sofia Avnet; Silvia Lemma; Margherita Cortini; Paola Pellegrini; Francesca Perut; Nicoletta Zini; Katsuyuki Kusuzaki; Tokuhiro Chano; Giulia Grisendi; Massimo Dominici; Angelo De Milito; Nicola Baldini
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.